|A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis|
S De Vita, L Quartuccio, M Isola, C Mazzaro, P Scaini, M Lenzi, ...
Arthritis & Rheumatism 64 (3), 843-853, 2012
|Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study|
X Mariette, R Seror, L Quartuccio, G Baron, S Salvin, M Fabris, ...
Annals of the rheumatic diseases 74 (3), 526-531, 2015
|Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients|
M Pietrogrande, S De Vita, AL Zignego, P Pioltelli, D Sansonno, S Sollima, ...
Autoimmunity reviews 10 (8), 444-454, 2011
|Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids|
L Quartuccio, G Soardo, G Romano, F Zaja, CA Scott, G De Marchi, ...
Rheumatology 45 (7), 842-846, 2006
|Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients|
C Baldini, P Pepe, L Quartuccio, R Priori, E Bartoloni, A Alunno, ...
Rheumatology 53 (5), 839-844, 2014
|Preliminary classification criteria for the cryoglobulinaemic vasculitis|
S De Vita, F Soldano, M Isola, G Monti, A Gabrielli, A Tzioufas, C Ferri, ...
Annals of the rheumatic diseases 70 (7), 1183-1190, 2011
|BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands|
L Quartuccio, S Salvin, M Fabris, M Maset, E Pontarini, M Isola, S De Vita
Rheumatology 52 (2), 276-281, 2013
|Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in …|
L Quartuccio, M Fabris, S Salvin, F Atzeni, M Saracco, M Benucci, ...
Rheumatology 48 (12), 1557-1559, 2009
|B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection|
M Fabris, L Quartuccio, S Sacco, G De Marchi, G Pozzato, C Mazzaro, ...
Rheumatology 46 (1), 37-43, 2007
|Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study|
L Quartuccio, M Isola, C Baldini, R Priori, EB Bocci, F Carubbi, M Maset, ...
Journal of autoimmunity 51, 75-80, 2014
|Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study|
L Cavagna, L Nuno, CA Scire, M Govoni, FJL Longo, F Franceschini, ...
Medicine 94 (32), 2015
|Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care|
L Quartuccio, A Sonaglia, D McGonagle, M Fabris, M Peghin, D Pecori, ...
Journal of Clinical Virology 129, 104444, 2020
|Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations|
P Brito-Zerón, E Theander, C Baldini, R Seror, S Retamozo, L Quartuccio, ...
Expert review of clinical immunology 12 (2), 137-156, 2016
|Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population‐based multicentre cohort study|
E Bartoloni, C Baldini, G Schillaci, L Quartuccio, R Priori, F Carubbi, V Bini, ...
Journal of internal medicine 278 (2), 185-192, 2015
|Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study|
S De Vita, L Quartuccio, R Seror, S Salvin, P Ravaud, M Fabris, ...
Rheumatology 54 (12), 2249-2256, 2015
|International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis …|
R Giacomelli, A Afeltra, A Alunno, C Baldini, E Bartoloni-Bocci, ...
Autoimmunity Reviews 16 (9), 911-924, 2017
|Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data …|
P Brito-Zerón, N Acar-Denizli, M Zeher, A Rasmussen, R Seror, ...
Annals of the rheumatic diseases 76 (6), 1042-1050, 2017
|Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy|
S De Vita, L Quartuccio, S Salvin, L Picco, CA Scott, M Rupolo, M Fabris
Clin Exp Rheumatol 32 (4), 490-4, 2014
|Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives|
M Infantino, A Damiani, FL Gobbi, V Grossi, B Lari, D Macchia, P Casprini, ...
Isr Med Assoc J 22 (4), 203-210, 2020
|Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution|
L Quartuccio, C Baldini, E Bartoloni, R Priori, F Carubbi, L Corazza, ...
Autoimmunity reviews 14 (11), 1019-1022, 2015